Entresto for Tetralogy of Fallot and Ebstein's Anomaly

Overseen By Amanda Wozniak

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Recruiting

Sponsor: Mayo Clinic

Must not be taking: ACE inhibitors, ARBs, ARNI, others

Disqualifiers: Chronic kidney disease, Hyperkalemia, Hypotension, Pregnancy, others

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to compare changes in RV structure and function, biomarkers, and patient reported outcomes between TOF patients randomized to an ARNI vs placebo.

Will I have to stop taking my current medications?

Yes, you will need to stop taking certain medications if you join this trial. Specifically, you cannot take medications like ACE inhibitors, ARBs, ARNIs, and several others listed in the exclusion criteria.

Is Entresto safe for humans?

There is no specific safety data for Entresto in the context of Tetralogy of Fallot or Ebstein's Anomaly, but Entresto has been studied and used safely in humans for other heart conditions, such as heart failure. ^{1 2 3 4 5}

How is the drug Entresto unique for treating Tetralogy of Fallot and Ebstein's Anomaly?

Entresto is unique because it combines two medications, sacubitril and valsartan, which work together to reduce strain on the heart by lowering blood pressure and improving heart function. This dual action may offer a novel approach compared to traditional surgical treatments for congenital heart defects like Tetralogy of Fallot and Ebstein's Anomaly, which primarily focus on correcting structural issues. ^{6 7 8 9 10}

Research Team

Alexander Egbe, MBBS, MPH

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for patients with specific heart conditions known as Tetralogy of Fallot (TOF) and Ebstein's Anomaly (EA). Participants should meet certain health criteria to be included, but the provided information does not specify these. People with other conditions that could interfere with the study or pose a risk may be excluded.

Inclusion Criteria

TOF or EA

I am 18 years old or older.

Exclusion Criteria

I am diagnosed with diabetes and am taking Aliskiren.

Hyperkalemia defined as serum potassium >5.2 mmol/l

Pregnancy

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Entresto or placebo to assess changes in RV structure and function, biomarkers, and patient-reported outcomes

52 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Entresto (Angiotensin Receptor Neprilysin Inhibitor)

Trial Overview The study is testing Entresto, a medication for heart failure, against a placebo in patients with TOF and EA. It aims to observe any changes in the right ventricle's structure and function, biomarker levels, and patient-reported outcomes when taking Entresto compared to not receiving it.

Participant Groups

Group I: Entresto Experimental Treatment 1 Intervention

Group II: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials

3,987

Recruited

47,860,000+

Findings from Research

In a study of 341 adults with repaired tetralogy of Fallot, it was found that survival rates were significantly lower compared to the general population, especially in males over 55 years, indicating a heightened risk of premature death and arrhythmia.

Pulmonary valve replacement reduced right ventricle volumes and QRS duration but paradoxically increased the risk of adverse outcomes, suggesting that while it may alleviate some physical symptoms, it does not necessarily improve overall survival or exercise capacity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Outcomes of adults with repaired tetralogy of Fallot from the national Scottish Cohort. Dobson, RJ., Ramparsad, N., Walker, NL., et al.[2021]

In a systematic review of 21 studies involving 610 fetuses with Ebstein anomaly or tricuspid valve dysplasia, transplacental NSAID therapy resulted in significantly higher live birth rates (86%) and survival to hospital discharge (89%) compared to expectant management (67% and 43%, respectively).

While NSAID therapy showed potential benefits in improving outcomes, it was also associated with higher rates of complications such as moderate to severe tricuspid regurgitation and oligohydramnios, highlighting the need for caution and further research on its safety.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Transplacental non-steroidal anti-inflammatory drugs versus expectant management in fetal Ebstein anomaly with circular shunt: Systematic review and meta-analysis. Mustafa, HJ., Aghajani, F., Bairmani, ZA., et al.[2023]

A machine learning model developed from clinical and cardiovascular data was able to predict major adverse cardiovascular events (MACE) in adults with repaired tetralogy of Fallot with a strong accuracy (area under the curve of 0.82) over a 5-year period, outperforming traditional prediction methods.

The model's effectiveness remained high even when limited to the top 10 predictive features, indicating that it can reliably use readily available clinical data for risk assessment, although removing exercise-related parameters decreased its predictive power.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Machine Learning for Prediction of Adverse Cardiovascular Events in Adults With Repaired Tetralogy of Fallot Using Clinical and Cardiovascular Magnetic Resonance Imaging Variables. Ishikita, A., McIntosh, C., Hanneman, K., et al.[2023]

Advancements in cardiology have enabled many patients with congenital heart defects to live into adulthood, but they often face complications related to their defects or treatments, necessitating adult cardiologists to understand these conditions.

The guide provides essential information on common congenital heart defects seen in adults, including their anatomy, physiology, clinical presentations, complications, and treatment options, which is crucial for effective ongoing care.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Congenital Heart Defects in Adults : A Field Guide for Cardiologists. Romfh, A., Pluchinotta, FR., Porayette, P., et al.[2021]

In a study of 85 adults with repaired tetralogy of Fallot (rTOF), pulmonary regurgitation and right ventricular outflow tract (RVOT) aneurysm or akinesia were found to be independently associated with right ventricular dilation and hypertrophy, which negatively impacted heart function.

The presence of RVOT aneurysm/akinesia was common in these patients and correlated with lower right ventricular ejection fraction (RVEF), highlighting the importance of maintaining pulmonary valve function to preserve overall heart health in individuals with rTOF.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. Davlouros, PA., Kilner, PJ., Hornung, TS., et al.[2019]

References

1. England pubmed.ncbi.nlm.nih.gov

Outcomes of adults with repaired tetralogy of Fallot from the national Scottish Cohort. [2021]

2. England pubmed.ncbi.nlm.nih.gov

Transplacental non-steroidal anti-inflammatory drugs versus expectant management in fetal Ebstein anomaly with circular shunt: Systematic review and meta-analysis. [2023]

3. United States pubmed.ncbi.nlm.nih.gov

The adult patient with Ebstein anomaly. Outcome in 72 unoperated patients. [2019]

4. United States pubmed.ncbi.nlm.nih.gov

Machine Learning for Prediction of Adverse Cardiovascular Events in Adults With Repaired Tetralogy of Fallot Using Clinical and Cardiovascular Magnetic Resonance Imaging Variables. [2023]

5. Netherlands pubmed.ncbi.nlm.nih.gov

Surgical Correction for a Neonate With Ebstein's Anomaly Associated With Tetralogy of Fallot. [2017]

6. United States pubmed.ncbi.nlm.nih.gov

Congenital Heart Defects in Adults : A Field Guide for Cardiologists. [2021]

7. Israel pubmed.ncbi.nlm.nih.gov

The surgical correction of Fallot's tetralogy. [2007]

8. United States pubmed.ncbi.nlm.nih.gov

Unnatural history of tetralogy of Fallot: prospective follow-up of 40 years after surgical correction. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

Tetralogy of Fallot: transannular and right ventricular patching equally affect late functional status. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. [2019]